Meeting
2022 ASCO Annual Meeting
AMEERA-4: A preoperative window-of-opportunity (WOO) study to assess the pharmacodynamic (PD) activity of amcenestrant or letrozole in postmenopausal patients with ER+/HER2− primary breast cancer.
Presenter
Mario Campone, MD, PhD
Institut de Cancérologie de l'Ouest, René Gauducheau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT04191382
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 528)
DOI
10.1200/JCO.2022.40.16_suppl.528
Abstract #
528
Poster Bd #
300
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2020 ASCO Virtual Scientific Program
Phase II preoperative window study of SAR439859 versus letrozole in post-menopausal women with newly diagnosed estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Speaker: Mario Campone, MD, PhD
Videos & Slides
2023 ASCO Breakthrough
Delayed versus immediate use of zoledronic acid for postmenopausal patients with ER/PR positive early breast cancer who are using adjuvant letrozole.
Speaker: Mai Abdel Gelil, Assistant lecturer at Clinical Oncology Dep., Assuit University, Egypt
Videos & Slides
2021 ASCO Annual Meeting
AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).
Speaker: Sarat Chandarlapaty, MD, PhD
Videos & Slides
2021 ASCO Annual Meeting
Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC).
Speaker: Heather M. Moore, PhD